Tianeptine: The Legal Opioid Hiding in Gas Station Supplements
Tianeptine is sold in US gas stations as a "nootropic" or "mood enhancer" — but at the doses people actually take, it acts on the same mu-opioid receptors as oxycodone. It's a prescription antidepressant in parts of Europe, Asia, and Latin America; in the US it has never been approved as a medication and is not a federally controlled substance, creating a loophole that brands like Za Za and Tianaa have ridden to a growing toll of hospitalisations and deaths.
The opioid mechanism
At therapeutic antidepressant doses (12.5 mg 2–3 times daily), tianeptine acts through glutamate modulation. At supranormal doses (50–500+ mg/day), its activity at mu-opioid and delta-opioid receptors dominates. Users seeking euphoria escalate rapidly; tolerance develops; withdrawal resembles opioid withdrawal with anxiety, sweating, tachycardia, and severe dysphoria. Physical dependence is well documented.
Poison control and death data
CDC analysis of poison control data found tianeptine exposure cases in the US rose from 11 in 2014 to over 150 per year by the early 2020s. Kentucky, Florida, Georgia, Tennessee, Alabama, and Michigan have each scheduled tianeptine as a controlled substance in response to local epidemics. Several states have reported overdose deaths, sometimes in combination with other substances.
The gas-station problem
Tianeptine products are sold in gas stations, head shops, and online with friendly packaging that obscures the pharmacology. Buyers frequently do not know they are taking an opioid-like substance with dependence potential. Hospital presentations involve patients seeking help for "supplement withdrawal" without realising they are opioid-dependent.
Emergency department presentations
Acute toxicity can include respiratory depression, cardiac arrhythmia, seizures, and coma. Withdrawal typically starts within 12 hours of last use and peaks at 36–72 hours. Buprenorphine can treat both acute intoxication (in overdose) and withdrawal; naloxone has variable effectiveness.
Regulatory action
FDA has issued warning letters to multiple tianeptine distributors and there have been seizures. The DEA has considered federal scheduling. Until federal action is complete, tianeptine remains legally available in many US states despite clear evidence of abuse potential.
If you or someone you know is using
Treat this as an opioid use disorder, not a supplement problem. Contact SAMHSA’s helpline (1-800-662-4357) or an addiction medicine physician. Abrupt discontinuation from high-dose daily use causes significant withdrawal; medically supervised tapering or buprenorphine induction is often required.
Sources
- El Zahran T, Schier J, Glidden E, et al. "Characteristics of tianeptine exposures reported to the National Poison Data System — United States, 2000–2017." MMWR Morbidity and Mortality Weekly Report, 2018;67(30):815–818. PMID 29851941.
- Edinoff AN, Sall S, Roberts TD, et al. "Tianeptine, an antidepressant with opioid agonist effects: pharmacology and abuse potential, a narrative review." Pain and Therapy, 2023;12(5):1121–1134.
- Lauhan R, Hsu A, Alam A, Beizai K. "Tianeptine abuse and dependence: case report and literature review." Psychosomatics, 2018;59(6):547–553.
- Smith KE, Rogers JM, Schriefer D, Grundmann O. "Tianeptine misuse and abuse: a review of the literature with a focus on emerging trends in the United States." Substance Use & Misuse, 2021;56(11):1617–1622.
- Wagner ML, Pergolizzi J Jr, LeQuang JK, Breve F, Magnusson P. "From "Zaza" to "tianna": non-prescribed use of tianeptine in the United States." Health Psychology Research, 2023;11:67890.
- Rushton W, Whitworth B, Brown J, Kurz M, Rivera J. "Characteristics of tianeptine effects reported to a poison control center: a growing threat to the United States?" Clinical Toxicology, 2021;59(11):1024–1029.
- U.S. Food & Drug Administration. "FDA warns consumers not to purchase or use any product containing tianeptine" (multiple warning letters and consumer alerts, 2018–2024). FDA.gov.
- State scheduling actions: Michigan (2018), Alabama (2021), Tennessee (2022), Kentucky (2022), Georgia (2023), Florida (2023), Indiana (2024), among others — classifying tianeptine as a Schedule I or analogous controlled substance under state law.
- U.S. Substance Abuse and Mental Health Services Administration. "National Helpline: 1-800-662-HELP (4357)" — free, confidential treatment referral and information service. samhsa.gov.